RU2018123502A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018123502A3 RU2018123502A3 RU2018123502A RU2018123502A RU2018123502A3 RU 2018123502 A3 RU2018123502 A3 RU 2018123502A3 RU 2018123502 A RU2018123502 A RU 2018123502A RU 2018123502 A RU2018123502 A RU 2018123502A RU 2018123502 A3 RU2018123502 A3 RU 2018123502A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562261815P | 2015-12-01 | 2015-12-01 | |
US62/261,815 | 2015-12-01 | ||
PCT/US2016/064414 WO2017096039A1 (en) | 2015-12-01 | 2016-12-01 | Scalable methods for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical use |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2018123502A RU2018123502A (ru) | 2020-01-14 |
RU2018123502A3 true RU2018123502A3 (ru) | 2020-04-20 |
RU2766583C2 RU2766583C2 (ru) | 2022-03-15 |
Family
ID=58797705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2018123502A RU2766583C2 (ru) | 2015-12-01 | 2016-12-01 | Масштабируемые способы получения рекомбинантного вектора на основе аденоассоциированного вируса (aav) в системе бессывороточной суспензионной культуры клеток, подходящего для клинического применения |
Country Status (16)
Country | Link |
---|---|
US (1) | US20190292561A1 (ru) |
EP (1) | EP3384015A4 (ru) |
JP (2) | JP7444521B2 (ru) |
KR (1) | KR20180091863A (ru) |
CN (1) | CN108603174A (ru) |
AU (2) | AU2016362317B2 (ru) |
BR (1) | BR112018011193A2 (ru) |
CA (1) | CA3006309A1 (ru) |
CO (1) | CO2018006699A2 (ru) |
IL (1) | IL259595B2 (ru) |
MX (2) | MX2018006682A (ru) |
PE (2) | PE20181534A1 (ru) |
PH (1) | PH12018501168A1 (ru) |
RU (1) | RU2766583C2 (ru) |
SG (2) | SG11201804400SA (ru) |
WO (1) | WO2017096039A1 (ru) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
US10335466B2 (en) | 2014-11-05 | 2019-07-02 | Voyager Therapeutics, Inc. | AADC polynucleotides for the treatment of parkinson's disease |
GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
CN112410339A (zh) | 2014-11-14 | 2021-02-26 | 沃雅戈治疗公司 | 调节性多核苷酸 |
JP2017535266A (ja) | 2014-11-14 | 2017-11-30 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | 筋萎縮性側索硬化症(als)を治療する組成物および方法 |
EP3230441A4 (en) | 2014-12-12 | 2018-10-03 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
IL292830B2 (en) | 2015-09-28 | 2023-06-01 | Univ Florida | Methods and compositions for stealth virus antibody vectors |
BR112018011193A2 (pt) * | 2015-12-01 | 2018-11-21 | Spark Therapeutics Inc | métodos escalonáveis para produzir vetor viral adeno-associado (aav) recombinante em sistema de cultura celular em suspensão isento de soro adequado para uso clínico |
US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
AU2017267665C1 (en) | 2016-05-18 | 2023-10-05 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
JP7220080B2 (ja) | 2016-05-18 | 2023-02-09 | ボイジャー セラピューティクス インコーポレイテッド | ハンチントン病治療組成物及び方法 |
JP2019530737A (ja) | 2016-08-23 | 2019-10-24 | アコーオス インコーポレイテッド | ヒト対象において非加齢性聴力障害を治療するための組成物および方法 |
US11298041B2 (en) | 2016-08-30 | 2022-04-12 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
AU2018261003A1 (en) | 2017-05-05 | 2019-11-14 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's Disease |
SG11201909870SA (en) | 2017-05-05 | 2019-11-28 | Voyager Therapeutics Inc | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
MX2020000216A (es) * | 2017-06-30 | 2020-09-03 | Spark Therapeutics Inc | Metodos de purificacion por columna de vectores aav. |
JP7229989B2 (ja) | 2017-07-17 | 2023-02-28 | ボイジャー セラピューティクス インコーポレイテッド | 軌道アレイガイドシステム |
US11512327B2 (en) | 2017-08-03 | 2022-11-29 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of AAV |
EP4124658A3 (en) | 2017-10-16 | 2023-04-19 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
WO2019079496A2 (en) * | 2017-10-18 | 2019-04-25 | Regenxbio, Inc. | FULLY HUMAN ANTIBODY-BASED THERAPEUTIC AGENTS HAVING POST-TRANSLATION MODIFICATION |
EP3720500A4 (en) * | 2017-12-05 | 2021-08-25 | Applied Genetic Technologies Corporation | FORMULATION OPTIMIZATION FOR VIRAL PARTICLES |
CA3094311A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Antibody-evading virus vectors |
CN108866011A (zh) * | 2018-07-31 | 2018-11-23 | 深圳生生凡非基因技术有限公司 | 一种同步包装rAAV的方法 |
US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
CN110437317B (zh) * | 2019-01-30 | 2023-05-02 | 上海科技大学 | 具有变异衣壳蛋白的腺相关病毒及其用途 |
JP7305115B2 (ja) * | 2019-02-11 | 2023-07-10 | エクセルジェネ エス.ア. | 新規な真核細胞形質転換システムシステム及び関連する方法 |
CN113727992A (zh) | 2019-03-21 | 2021-11-30 | 斯特里迪比奥公司 | 重组腺相关病毒载体 |
WO2021028837A1 (en) | 2019-08-13 | 2021-02-18 | Waters Technologies Corporation | Affinity resins and sample preparation devices based on cartilaginous fish ignar derived binding domains |
CA3157700A1 (en) | 2019-10-17 | 2021-04-22 | Stridebio, Inc. | Adeno-associated viral vectors for treatment of niemann-pick disease type c |
CN110894494B (zh) * | 2019-11-22 | 2022-09-27 | 广西梧州制药(集团)股份有限公司 | 一种大规模高密度悬浮培养293细胞高产腺病毒的方法 |
CN110938654A (zh) * | 2019-12-11 | 2020-03-31 | 和元生物技术(上海)股份有限公司 | 一种细胞转染试剂及其应用 |
JP2023510590A (ja) * | 2020-01-17 | 2023-03-14 | アスクレピオス バイオファーマシューティカル, インコーポレイテッド | 組換えaavの産生 |
CA3168055A1 (en) | 2020-02-21 | 2021-08-26 | Emmanuel John Simons | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
WO2022043926A1 (en) * | 2020-08-31 | 2022-03-03 | Intas Pharmaceuticals Ltd. | Process for preparation of recombinant adeno-associated virus particle |
JP2023546113A (ja) | 2020-10-15 | 2023-11-01 | エフ. ホフマン-ラ ロシュ アーゲー | 同時遺伝子活性化のための核酸構築物 |
JP2023546116A (ja) | 2020-10-15 | 2023-11-01 | エフ. ホフマン-ラ ロシュ アーゲー | Va rna転写のための核酸構築物 |
WO2022229853A1 (en) * | 2021-04-27 | 2022-11-03 | Novartis Ag | Viral vector production system |
WO2023198685A1 (en) | 2022-04-13 | 2023-10-19 | F. Hoffmann-La Roche Ag | Method for determining aav genomes |
EP4279599A1 (en) * | 2022-05-18 | 2023-11-22 | Branca Bunus Limited | Ordered formulation method to construct polyplex with core-aggregate structure |
WO2023227438A1 (en) | 2022-05-23 | 2023-11-30 | F. Hoffmann-La Roche Ag | Raman-based method for the differentiation of aav particle serotype and aav particle loading status |
WO2023232922A1 (en) | 2022-06-03 | 2023-12-07 | F. Hoffmann-La Roche Ag | Method for producing recombinant aav particles |
WO2024013239A1 (en) | 2022-07-14 | 2024-01-18 | F. Hoffmann-La Roche Ag | Method for producing recombinant aav particles |
WO2024056561A1 (en) | 2022-09-12 | 2024-03-21 | F. Hoffmann-La Roche Ag | Method for separating full and empty aav particles |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1944362T3 (en) * | 1997-09-05 | 2016-01-25 | Genzyme Corp | Fremgangsmåder til fremstilling af hjælpevirusfri præparater med høj titer af rekombinante AAV-vektorer |
US6995006B2 (en) * | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6593123B1 (en) * | 2000-08-07 | 2003-07-15 | Avigen, Inc. | Large-scale recombinant adeno-associated virus (rAAV) production and purification |
US7829694B2 (en) * | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US7605249B2 (en) * | 2002-11-26 | 2009-10-20 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
RU2303064C2 (ru) * | 2005-04-06 | 2007-07-20 | ГУ НИИ вирусных препаратов им. О.Г. Анджапаридзе РАМН | Молекулярный комплекс для трансфекции клеток млекопитающих, содержащий плазмидную днк, модифицированный полиэтиленимин и молекулы-лиганды |
CN104520428B (zh) * | 2012-02-17 | 2018-09-21 | 费城儿童医院 | 将基因转移到细胞、器官和组织的aav载体组合物和方法 |
JP6480910B6 (ja) * | 2013-03-15 | 2019-04-03 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | 無血清懸濁培養物系で組み換えレンチウイルスベクターを産生するための拡張可能な生産プロセス |
EP3567112A1 (en) * | 2013-06-13 | 2019-11-13 | Translate Bio, Inc. | Messenger rna based viral production |
CN103329852B (zh) * | 2013-06-19 | 2015-10-07 | 中国医学科学院病原生物学研究所 | 一种hbv持续性感染及纤维化小鼠模型建立 |
JP6609246B2 (ja) * | 2013-06-28 | 2019-11-20 | エスリス ゲーエムベーハー | 細胞内へのrna導入用組成物 |
SG10201809075XA (en) * | 2013-07-22 | 2018-11-29 | Childrens Hospital Philadelphia | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues |
WO2015023775A1 (en) * | 2013-08-13 | 2015-02-19 | Baylor College Of Medicine | A novel plga-modified polyethylenimine self-assembly nanotechnology for nucleic acid and drug delivery |
BR112018011193A2 (pt) * | 2015-12-01 | 2018-11-21 | Spark Therapeutics Inc | métodos escalonáveis para produzir vetor viral adeno-associado (aav) recombinante em sistema de cultura celular em suspensão isento de soro adequado para uso clínico |
SG11201911603SA (en) * | 2017-06-07 | 2020-01-30 | Spark Therapeutics Inc | ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION |
-
2016
- 2016-12-01 BR BR112018011193A patent/BR112018011193A2/pt active Search and Examination
- 2016-12-01 JP JP2018527766A patent/JP7444521B2/ja active Active
- 2016-12-01 CN CN201680070540.4A patent/CN108603174A/zh active Pending
- 2016-12-01 MX MX2018006682A patent/MX2018006682A/es unknown
- 2016-12-01 RU RU2018123502A patent/RU2766583C2/ru active
- 2016-12-01 KR KR1020187018714A patent/KR20180091863A/ko not_active Application Discontinuation
- 2016-12-01 PE PE2018001066A patent/PE20181534A1/es unknown
- 2016-12-01 WO PCT/US2016/064414 patent/WO2017096039A1/en active Application Filing
- 2016-12-01 AU AU2016362317A patent/AU2016362317B2/en not_active Ceased
- 2016-12-01 US US15/780,542 patent/US20190292561A1/en active Pending
- 2016-12-01 EP EP16871497.0A patent/EP3384015A4/en active Pending
- 2016-12-01 CA CA3006309A patent/CA3006309A1/en active Pending
- 2016-12-01 CO CONC2018/0006699A patent/CO2018006699A2/es unknown
- 2016-12-01 SG SG11201804400SA patent/SG11201804400SA/en unknown
- 2016-12-01 IL IL259595A patent/IL259595B2/en unknown
- 2016-12-01 SG SG10202106287YA patent/SG10202106287YA/en unknown
- 2016-12-01 PE PE2023002040A patent/PE20240371A1/es unknown
-
2018
- 2018-05-31 MX MX2023012498A patent/MX2023012498A/es unknown
- 2018-06-01 PH PH12018501168A patent/PH12018501168A1/en unknown
-
2022
- 2022-02-28 JP JP2022029167A patent/JP2022071049A/ja active Pending
-
2023
- 2023-02-20 AU AU2023200992A patent/AU2023200992A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112018011193A2 (pt) | 2018-11-21 |
CO2018006699A2 (es) | 2018-09-20 |
PH12018501168A1 (en) | 2019-01-21 |
AU2023200992A1 (en) | 2023-05-18 |
MX2023012498A (es) | 2023-11-03 |
EP3384015A1 (en) | 2018-10-10 |
IL259595B1 (en) | 2023-09-01 |
JP7444521B2 (ja) | 2024-03-06 |
PE20181534A1 (es) | 2018-09-26 |
EP3384015A4 (en) | 2019-05-29 |
MX2018006682A (es) | 2018-09-26 |
SG11201804400SA (en) | 2018-06-28 |
US20190292561A1 (en) | 2019-09-26 |
AU2016362317A1 (en) | 2018-06-14 |
IL259595A (en) | 2018-07-31 |
AU2016362317B2 (en) | 2023-03-16 |
PE20240371A1 (es) | 2024-03-05 |
CA3006309A1 (en) | 2017-06-08 |
RU2766583C2 (ru) | 2022-03-15 |
CN108603174A (zh) | 2018-09-28 |
KR20180091863A (ko) | 2018-08-16 |
JP2018535682A (ja) | 2018-12-06 |
WO2017096039A1 (en) | 2017-06-08 |
JP2022071049A (ja) | 2022-05-13 |
RU2018123502A (ru) | 2020-01-14 |
IL259595B2 (en) | 2024-01-01 |
SG10202106287YA (en) | 2021-07-29 |